BiliaryTractCancer near Teaneck, NJ

Biography: Manuel Hidalgo, M.D., Ph.D., is currently the Chief of the Division of Hematology and Medical Oncology at Weill Cornell Medicine/NewYork-Presbyterian Hospital. Dr. Hidalgo received his M.D. from the University of Navarra in Pamplona, Spain in 1992, and Ph.D. from University Autonoma of Madrid in 1997. He trained in medicine and medical oncology at Hospital "12 de Octubre" in Madrid and at the University of Texas Health Science Center in San Antonio, Texas. He also completed a fellowship program in anticancer drug development at the Institute of Drug Development in San Antonio. Prior to this position, he served as an Assistant Professor of Medicine at the Division of Hematology and Oncology at the University of Texas Health Science Center in San Antonio. In 2001, Dr. Hidalgo relocated to Johns Hopkins University to serve as Director of the Gastrointestinal Oncology Program at the Kimmel Comprehensive Cancer Center, where he also held the title of Associate Professor of Oncology. Dr. Hidalgo became Director of the Clinical Research Program at the Spanish National Cancer Center in 2009 and Vice Director of Translational Research in 2011. In 2015, he became the Chief of the Division of Hematology and Oncology and Director of the Rosenberg Clinical Cancer Center at the Beth Israel Deaconess Medical Center in Boston. Dr. Hidalgo also served as the Theodore W. and Evelyn G. Berenson Professor of Medicine at Harvard Medical School. His main focus of research has been new drug development in pancreatic cancer. His group popularized the use of Avatar mouse models for cancer research and recently contributed to the development and Federal Drug Administration (FDA) approval of nab-paclitaxel for pancreatic cancer treatment. Dr. Hidalgo's current research focuses on strategies for personalized medicine and immunotherapy in pancreatic cancer. Dr. Hidalgo also serves on the Board of Directors for Bristol Myers Squibb (BMS).

Biography: Alexandra Gomez Arteaga, M.D., is Assistant Professor of Medicine in the Division of Hematology and Medical Oncology at Weill Cornell Medicine/New York-Presbyterian Hospital. She specializes in the care of patients with hematological malignancies and other disorders who need a blood or bone marrow stem cell transplant or cellular therapies.Dr. Gomez received her M.D. (Valedictorian) from Los Andes University in Bogota, Colombia, in 2011. She completed her Internal Medicine residency at the University of Miami/Jackson Memorial Hospital and her Hematology/Oncology fellowship at Weill Cornell Medicine/New York-Presbyterian Hospital, where she also served as Chief Fellow. Subsequently, she completed an advanced fellowship in Bone Marrow Transplantation at Memorial Sloan Kettering Cancer Center. Upon completion of her training, Dr. Gomez was recruited back to Weill Cornell Medicine/New York-Presbyterian Hospital to join the faculty of the Bone Marrow Transplant Program.Dr. Gomez's main research focus is relapse prevention strategies and management of disease relapse after a stem cell transplant. She has published in leading internationally circulated peer-reviewed journals, among them Cancer, Biology of Blood and Marrow Transplantation, Bone Marrow Transplantation, the American Journal of Hematology, Leukemia & Lymphoma. She is a member of the American Society for Transplantation and Cellular Therapy (ASTCT), the American Society of Hematology (ASH), the American Society of Clinical Oncology (ASCO), and the Society for Immunotherapy of Cancer (SITC).

Care Philosophy: I am a medical oncologist specializing in the treatment of patients with genitourinary malignancies (including prostate, bladder, testes, and kidney cancers). My clinical and translational research focuses on development of new treatment strategies for patients. In particular, I am studying the genetics of prostate cancer, and I am involved in developing personalized treatment approaches for patients based on their cancer's specific molecular alterations. My clinical practice and research rely on close collaborations with clinicians, scientists, and physician scientists from multiple disciplines including pathology, urology, radiology, radiation oncology, computational biology, pharmacology, and medical oncology. Most recently, we have expanded these clinical and research efforts across cancer types as part of our new Institute for Precision Medicine

Biography: Dr. Erin Mulvey is an Assistant Professor of Medicine in the Division of Hematology and Medical Oncology at Weill Cornell Medicine. She is also an assistant attending physician at NewYork-Presbyterian Queens, She completed her undergraduate education at Boston University where she earned a degree in Biochemistry and Molecular Biology. She received her medical degree from New York Medical College. Dr. Mulvey completed both her Residency in Internal Medicine and her Fellowship in Hematology/Oncology at NewYork-Presbyterian Hospital and Weill Cornell Medical College.

Biography: Elizabeth Gorman, MD is an Assistant Professor of Surgery in Weill Cornell Medicine's Division of Trauma, Burns, Acute and Critical Care Surgery. Dr. Gorman graduated Cum Laude from Dartmouth College. Subsequently, she received her medical degree from University of Texas Southwestern Medical School. She completed her general surgery residency at NYU Langone Medical Center and spent an additional year as a clinical research fellow. She then pursued fellowship training in Surgical Critical Care and Acute Care Surgery at Rutgers New Jersey Medical School. Dr. Gorman is board certified in General Surgery and Surgical Critical Care.View Research Publications

Biography: Ghaith Abu-Zeinah, MD, is an Assistant Professor in Medicine at Weill Cornell Medical College and an Assistant Attending Physician at the NewYork-Presbyterian Hospital. Dr. Abu-Zeinah earned his M.D. with academic distinction from the Weill Cornell Medical College in Qatar in 2013. He completed his residency training in Internal Medicine (2016) and fellowship training in Hematology/Oncology (2019) at the NewYork-Presbyterian Hospital/Weill Cornell Medicine in New York City.Dr. Abu-Zeinah is a Hematologist and Oncologist with a specialty practice in Myeloproliferative Neoplasms (MPN). His laboratory and clinical research is focused on identifying and developing therapies that target the malignant stem cells in patients with MPN. He received several awards for his work and presented at national conferences including the International Congress on Myeloproliferative Neoplasms and the American Society of Hematology. He has joined the Richard T Silver MPN Center as a physician-scientist both treating patients and conducting research.

Biography: Nicole D. Goulet is a Trauma and Acute Care Surgeon. Dr. Goulet earned her undergraduate degree from Smith College. She completed her medical educationand residency at University of Connecticut. She then went on to complete her Trauma and Critical Care Fellowship and her first year in practice at Rutgers University in Newark, NJ before she began working at NYU Langone in 2018. She served as the Director of the Surgical Intensive Care Unit in Brooklyn, NY for the past three years.Dr. Goulet is one of the founders of the Association of Out Surgeons and Allies (AOSA) and was the Founding President. She is also a member of several trauma organizations including the American Association for the Surgeryof Trauma (AAST) and Eastern Association for the Surgery of Trauma (EAST) as well as the Association for Academic Surgery (AAS) where she serves on Diversity, Equity and Inclusion (DEI) committees. She has published several articles on diversity and equity in surgery which is her primary research focus.

Biography: Dr. Chris Hackett received his BS in Biological Sciences from Stanford University in 2000. After doing biomedical research in industry and academia, he then pursued graduate studies in cancer genomics at the University of California, San Francisco, where he earned his PhD in 2010. Seeking to become a physician-scientist, he then earned his medical degree (MD) from the University of Minnesota in 2014. He then completed his Internal Medicine Residency at NewYork-Presbyterian/Weill Cornell Medical Center, followed by a fellowship in Medical Oncology at Memorial Sloan Kettering Cancer Center (MSK), where he focused on solid tumor oncology in the clinic and carried out laboratory research to design T cell therapies for cancer. Following fellowship, Dr. Hackett was an attending on the Cellular Therapeutics Service at MSK, where he focused on treating patients with CAR T cells, Tumor Infiltrating Lymphocytes (TIL) and other cell therapies. In 2023, he joined the Bone Marrow Transplant Service at Weill Cornell Medicine and NewYork-Presbyterian Hospital, where he continues to both treat patients with cellular therapies and conduct research to develop new cell therapies for solid tumors.